Kairos Pharma Stock Soars After Positive Interim Results From Phase 2 Trial Of ENV-105
Positive Trial Results: Kairos Pharma's shares surged 88.29% following positive interim safety results from its Phase 2 trial of ENV-105 in patients with metastatic castration-resistant prostate cancer, indicating the treatment was well tolerated without significant adverse effects.
Future Plans: The company intends to consult with regulatory agencies regarding a potential Phase 3 trial based on the encouraging data, with interim efficacy results expected by September 2025.
Trade with 70% Backtested Accuracy
Analyst Views on KAPA
About KAPA
About the author
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.
Market Winning Tools: Traders utilize Benzinga Pro's tools to gain a competitive edge and improve their trading success.
D. Boral Capital Upholds Buy Rating for Kairos Pharma (KAPA)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for Kairos Pharma (NYSEAM:KAPA), with a projected one-year price target of $8.50/share, indicating a potential upside of 632.76% from its current price of $1.16/share.
Fund Sentiment and Ownership: There has been a 44.44% increase in the number of funds reporting positions in Kairos Pharma, although total shares owned by institutions decreased by 84.77% over the last three months, with notable holdings from firms like XTX Topco and Aptus Capital Advisors.
Kairos Pharma Discusses Phase 2 Trial Results of ENV-105 for Advanced Prostate Cancer at ESMO Conference
Interim Efficacy Analysis: Kairos Pharma's Phase 2 trial of ENV-105, a CD105 antagonist, shows promising results in treating metastatic castration-resistant prostate cancer, with 86% of patients benefiting from the combination therapy with apalutamide, and many remaining progression-free for over a year.
Clinical Trial Leadership: The trial, led by Dr. Edwin Posadas, is currently enrolling up to 100 patients across multiple cancer centers, aiming to demonstrate improved disease control and tolerability compared to existing treatments like chemotherapy and radioligand therapy.
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
FedEx Shares Rise 5%; Check Out 20 Stocks Making Moves in Premarket Trading
FedEx Financial Results: FedEx Corporation's shares rose 4.8% in pre-market trading after reporting better-than-expected Q1 fiscal 2026 results, with projected revenue growth of 4% to 6% and plans for $1 billion in permanent cost reductions.
Pre-Market Stock Movements: AGM Group Holdings saw a significant 111.6% increase after a sale announcement, while other notable gainers included AlphaVest Acquisition Corp (+71.4%) and 22nd Century Group (+45.5%). Conversely, Reviva Pharmaceuticals experienced a sharp decline of 28.8% following a public offering announcement.
Kairos Pharma Wins 2025 Clinical Trials Arena R&D Award for Advanced Prostate Cancer
- Award Recognition: Kairos Pharma has been awarded the 2025 Clinical Trials Arena R&D Award for its innovative therapy ENV-105 in metastatic castration-resistant prostate cancer, highlighting its leadership in cancer treatment.
- Clinical Trial Results: In the Phase 2 trial of ENV-105 combined with apalutamide, 86% of patients showed clinical benefit, with all responders remaining progression-free for at least four months and some beyond one year, indicating the therapy's potential in patients with limited options.
- Targeted Therapy Strategy: ENV-105, as the first CD105-targeting monoclonal antibody, aims to overcome resistance following standard hormone treatments, emphasizing Kairos Pharma's innovative approach and scientific rigor in cancer therapy.
- Future Development Potential: The CEO of Kairos Pharma noted that the emerging clinical data supports the potential to extend disease control, offering new hope for patients facing treatment resistance and further advancing the company's strategic development in the biopharmaceutical sector.
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders to stay updated on market movements.
Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters for its users.
Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing collaboration and information sharing.
Market Winning Tools: Traders utilize Benzinga Pro's tools to gain a competitive edge and improve their trading success.
D. Boral Capital Upholds Buy Rating for Kairos Pharma (KAPA)
Analyst Recommendation: D. Boral Capital has maintained a Buy recommendation for Kairos Pharma (NYSEAM:KAPA), with a projected one-year price target of $8.50/share, indicating a potential upside of 632.76% from its current price of $1.16/share.
Fund Sentiment and Ownership: There has been a 44.44% increase in the number of funds reporting positions in Kairos Pharma, although total shares owned by institutions decreased by 84.77% over the last three months, with notable holdings from firms like XTX Topco and Aptus Capital Advisors.
Kairos Pharma Discusses Phase 2 Trial Results of ENV-105 for Advanced Prostate Cancer at ESMO Conference
Interim Efficacy Analysis: Kairos Pharma's Phase 2 trial of ENV-105, a CD105 antagonist, shows promising results in treating metastatic castration-resistant prostate cancer, with 86% of patients benefiting from the combination therapy with apalutamide, and many remaining progression-free for over a year.
Clinical Trial Leadership: The trial, led by Dr. Edwin Posadas, is currently enrolling up to 100 patients across multiple cancer centers, aiming to demonstrate improved disease control and tolerability compared to existing treatments like chemotherapy and radioligand therapy.
D. Boral Capital Reiterates Buy Rating on Kairos Pharma with $9 Price Target Intact
Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make winning trades in the stock market.
Exclusive Community: Joining Benzinga Pro connects users with over 10,000 serious traders and provides access to exclusive stories and insights from Benzinga reporters.
FedEx Shares Rise 5%; Check Out 20 Stocks Making Moves in Premarket Trading
FedEx Financial Results: FedEx Corporation's shares rose 4.8% in pre-market trading after reporting better-than-expected Q1 fiscal 2026 results, with projected revenue growth of 4% to 6% and plans for $1 billion in permanent cost reductions.
Pre-Market Stock Movements: AGM Group Holdings saw a significant 111.6% increase after a sale announcement, while other notable gainers included AlphaVest Acquisition Corp (+71.4%) and 22nd Century Group (+45.5%). Conversely, Reviva Pharmaceuticals experienced a sharp decline of 28.8% following a public offering announcement.
